New industry-first study found total strain and sprain injuries were reduced when warehouse workers across five sites wore back exosuits. NASHVILLE, Tenn.–(BUSINESS WIRE)–#exosuit—HeroWear, an occupational exoskeleton provider, has announced breakthrough longitudinal safety data from five distribution centers over 8 to 23 months and a combined 311,000 work hours, signifying a 62% reduction in total strain … [Read more…]

VANCOUVER, British Columbia–(BUSINESS WIRE)–WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (the “Company” or “WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce the release of a letter to shareholders from its Founder, Chairman and Chief Executive Officer, … [Read more…]

LUSAKA, Zambia–(BUSINESS WIRE)–Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA), has announced a new partnership with leading Zambian pharmaceutical manufacturer Pharmanova Zambia Limited to expand access to life‑saving zinc treatments for children across Zambia. The collaboration was formally celebrated during a ceremony in Lusaka with the Zambian Ministry of Health, … [Read more…]

BEIJING–(BUSINESS WIRE)–Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the “Company”), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following … [Read more…]

Access to Acceleration: Agenus’ BOT+BAL Global Momentum Entering 2026 Webcast on Wednesday, January 28, 2026, at 4:00 p.m. ET LEXINGTON, Mass.–(BUSINESS WIRE)–$AGEN #Access—Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus’ Global Momentum Entering 2026 on Wednesday, January 28, 2026, … [Read more…]

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Artemisinin Combination Therapy Market – Global Forecast 2026-2032” has been added to ResearchAndMarkets.com’s offering. The Artemisinin Combination Therapy (ACT) market exemplifies dynamic growth and promising potential in the treatment of malaria. Expected to increase from USD 386.40 million in 2025 to USD 608.26 million by 2032, supported by a steady CAGR of 6.69%, … [Read more…]

ASD Insight Test is a Critical Step in Redefining Autism as a Biologically Measurable Condition IRVINE, Calif.–(BUSINESS WIRE)–#AutismAwareness—NeuroQure, a pioneering leader in neurological diagnostics, announces the launch of ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth. Representing a critical step in redefining autism as a biologically measurable condition, ASD … [Read more…]

Rerouting Minds is designed to increase understanding of pharmaceutical lysergide (LSD) and the role of rigorous psychedelic research in addressing unmet needs in severe mental health disorders NEW YORK–(BUSINESS WIRE)–Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric … [Read more…]

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA for BCG-unresponsive papillary NMIBC The additional information does not include the initiation or design of any new clinical trials, and the Company will provide the requested … [Read more…]